Finasta

Active material: Finasteride
When ATH: G04CB01
CCF: Drug for the treatment of benign prostatic hyperplasia. Ингибитор 5a-редуктазы
When CSF: 28.01.01.01
Manufacturer: DR. REDDY`S LABORATORIES LTD. (India)

Pharmaceutical form, composition and packaging

Pills, Film-coated white, round, lenticular, signed “END” on one side and smooth – with another; of presentations – white or almost white mass.

Excipients: docusate sodium, sodium carboxymethyl starch (Type A), pregelatinized corn starch, lactose, magnesium stearate, microcrystalline cellulose (Ultra-102).

The composition of the coating film: gipromelloza (15 cps), propylene glycol, talc, Titanium dioxide.

10 PC. – strips (3) – packs cardboard.

Pharmacological action

Finasteride – 4-synthetic compound azasteroid, Competitors and specific inhibitor of steroid 5-alpha reductase – intracellular enzyme, which converts testosterone to 5-active androgen DHT (DGT). Tissue growth and development of prostate benign hyperplasia due to the conversion of testosterone to dihydrotestosterone in the prostate cells. Under the influence of the drug is a significant decrease in the concentration digidrosterona in blood plasma, and in prostate tissue. Finasteride does not bind to androgen receptors.

As a result of the drug decreases the size of the prostate, decreases symptoms, associated with BPH.

The drug had no effect on plasma lipid levels and cortisol levels, Estradiol, prolactin, TSH, tiroksina.

Pharmacokinetics

Absorption and distribution: After oral administration of finasteride is rapidly absorbed from the gastrointestinal tract. Bioavailability is about 80% and independent of food intake

Maximum plasma concentration is achieved in 1-2 hours after oral administration. Plasma protein binding is about 90%.

Metabolism and excretion: Finasteride is metabolized by the liver and is excreted as metabolites in the urine and feces.

Pharmacokinetics in special cases: the half-life of the drug in patients over 60 s is 6 hours, in patients over 70 years can be extended to 8 hours.

Testimony

• treatment of benign prostatic hyperplasia with a view:
• reduce the size of enlarged prostate,
• increasing the maximum speed of the flow of urine and reduce symptoms,
• associated with hyperplasia,
• reducing the risk of acute urinary retention and the associated probability of surgery.

Dosage regimen

Finasta appoint 5 mg 1 once a day, regardless of the meal.

Duration of therapy to assess its effectiveness must not be less than 6 months. Approximately 50% patients with disappearance of clinical symptoms occurred during the treatment 12 months.

Side effect

Allergic reactions, gynecomastia, impotence, reduced libido and decrease in ejaculate volume. The incidence of side effects than 3-4% and decreases during treatment. In some cases, there was increase in the level of luteinizing hormone and follicle-stimulating hormone and testosterone by approximately 10%, however, these parameters remained within normal limits.

Contraindications

• Hypersensitivity to finasteride and other ingredients,
• Obstructive uropathy, childhood.

Pregnancy and lactation

These are not represented.

Cautions

Before treatment is necessary to eliminate the disease Finasta, which may simulate benign prostatic hyperplasia, such as infectious prostatitis, prostate cancer, urethral stricture, hypotonic bladder, and a number of changes in the urinary system, occur in some diseases of the nervous system.

With care prescribe a drug to patients with impaired hepatic function.

Since the application of Finasta decrease prostate-specific antigen (on 41% and 48% according to 6 and 12 months of therapy), periodically during therapy is necessary to conduct a survey of patients to avoid their prostate cancer.

Women of childbearing age and pregnant women should avoid contact with the crushed pills Finasta, tk. the ability of the drug to inhibit the conversion of testosterone to DHT can cause developmental disorders of sex organs in a male fetus

Overdose

Currently, cases of drug overdose were reported Finasta.

Drug Interactions

No clinically significant drug interactions.

Conditions and terms

The drug should be stored in a dry, dark place at temperatures up to 25 ° C.

Keep out of reach of children!

Shelf life: 2 year.

Do not use beyond the expiration date, on the package.